Published: 3 March 2022

Publications

Recent approvals: New active ingredients or new indications

Published 3 March 2022
Prescriber Update 43(1): 9
March 2022

For the period 16 October 2021 to 15 January 2022.

Recent approvals of medicines with new active ingredients

Trade name (active ingredient) Dose form and strength(s) Therapeutic area
Cuprior (trientine) Film coated tablet
150 mg
Wilson's disease patients who are intolerant to D-penicillamine therapy
Mylotarg (gemtuzumab ozogamicin) Powder for injection
5 mg
CD33-positive acute myeloid leukaemia
Trikafta (elexacaftor/tezacaftor/ivacaftor + ivacaftor) Film coated tablet
100/50/75 mg + 150 mg
50/25/37.5 mg + 75 mg
Cystic fibrosis patients with at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
Ronapreve (casirivimab/imdevimab) Solution for injection or infusion, single-use or multiuse vials
120/120 mg/mL
COVID-19

Approved medicines with new indications

Trade Name (active ingredient) Dose form and strength(s) New therapeutic area(s)
Rinvoq (upadacitinib) Modified release tablet
15 mg
Psoriatic arthritis
Ankylosing spondylitis


See the Medsafe website for:

Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /